Immunohistochemistry (IHC) and in-situ hybridization (ISH) are well-known and routinely used techniques for the detection of specific proteins, antigens, and biomarkers of interest in tissue sections. The need for suitable controls is a key requirement for robust data interpretation for any technique – IHC and ISH are no exception.
How this collaboration works:
Receive one HER2 Dynamic Range Analyte Control CMA block consisting of four cores, 0, 1+ (both nonamplified), 2+ (equivocal) and 3+ (amplified). The block will yield over 300 sections to use as required.
This collaboration is open from April 2021 and will be renewed every three months until December 2021.
Please note: laboratories cannot simultaneously apply to this and other collaborations involving sponsorship of HistoCyte Dynamic Range Control blocks.
To benefit from this opportunity, please ensure that lab assay details in “Assay Management” section reflects the following information for Q4 2020 & Q1 2021:
· Breast Cancer disease volume and corresponding HER2 biomarker volume and testing method(s)/assay(s)
· Gastric Cancer disease volume and corresponding PD-L1 & HER2 biomarker volumes and testing methods/assays
· Triple Negative Breast Cancer disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assays(s)
The information above will help Diaceutics understand how testing is performed in your lab and will enable us to design strategies to support testing and patient treatment.
If your lab does not fulfill all the requirements and you are interested in this collaboration, please send us a message via “Ask a question”.